GlucoTrack, Inc. - Common Stock (NQ:GCTK)

1.210 -0.200 (-14.18%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GlucoTrack, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member

February 26, 2025

Leading diabetes researcher and clinician joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology

From Glucotrack, Inc.

Via GlobeNewswire

Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial

February 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial

February 25, 2025

By JE Insights, Benzinga

Via TheNewswire.com

What's going on in today's session ↗

February 05, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Via Chartmill

How Is The Market Feeling About GlucoTrack? ↗

January 22, 2025

Via Benzinga

Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session. ↗

February 04, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Tuesday's session: top gainers and losers ↗

February 04, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

February 04, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor

February 04, 2025

The study met its primary endpoint with no procedure or device related serious adverse events reported

From Glucotrack, Inc.

Via GlobeNewswire

Which stocks are most active on Thursday? ↗

January 30, 2025

Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

January 30, 2025

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 30, 2025

Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Glucotrack Announces Reverse Stock Split

January 30, 2025

1-for-20 reverse stock split to become effective as of the opening of trading on February 4, 2025

From Glucotrack, Inc.

Via GlobeNewswire

Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

January 29, 2025

Industry veteran Peter C. Wulff joins Glucotrack to drive financial strategy and commercialization of its continuous blood glucose monitor for people with diabetes

From Glucotrack, Inc.

Via GlobeNewswire

Glucotrack Announces ISO 13485:2016 Certification

January 21, 2025

ISO Certification highlights commitment to quality for continuous blood glucose monitor

From Glucotrack, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 16, 2025

Via Benzinga

Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket ↗

January 16, 2025

Via Benzinga

Glucotrack Strenghtens Leadership Team with Addition of Industry Veteran as Vice President of Regulatory Affairs

January 15, 2025

New hire set to drive clinical development and U.S. commercialization of the continuous blood glucose monitor for people with diabetes

From Glucotrack, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 15, 2025

Via Benzinga

Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket ↗

January 15, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

January 13, 2025

Via Benzinga

Glucotrack to Present at TechBio Showcase™ 2025

January 07, 2025

Presentation to feature an update on the Company’s novel continuous blood glucose monitor for patients with diabetes

From Glucotrack, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 06, 2025

Via Benzinga

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

December 05, 2024

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Via News Direct

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 13, 2024

Via Benzinga

S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results ↗

November 13, 2024

Via Benzinga

Topics Stocks

Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings ↗

November 13, 2024

Via Benzinga

Topics Stocks

US Stocks Mixed; Inflation Rate Increases In October ↗

November 13, 2024

Via Benzinga

Topics Economy

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.